TERT and thyroid cancer: However, samples from primary tumors were significantly less enriched with TERT promoter mutations than those from metastatic tumors in patients with melanoma (31%, n = 223/720 vs. 49.6%, n = 741/1495, respectively) (OR = 0.5; 95%CI, 0.4-0.6; Q < .001), soft-tissue sarcoma (6.3%, n = 99/1578 vs. 8.9%, n = 75/838, respectively) (OR = 0.7, 95%CI, 0.5-0.9; Q = .03), and thyroid cancer (35.2%, n = 177/503 vs. 48%, n = 217/452, respectively) (OR = 0.6; 95%CI, 0.5-0.8; Q < .001) (Supplementary Fig. S1; Supplementary Table S9,).